

Daughter..... Mobile No.

Others (Friend / accompanying person)..... Mobile No.

7.2 Code of Relative / Next of Kin (including parent) / Accompanying Person

- (1) Father (2) Mother (3) Husband
- (4) Wife (5) Son (6) Daughter
- (7) Other Relative / Friend / Neighbor (8) Others (9) Unknown

8. Place of Residence: Place of Usual Residence (where the patient has been residing for the past one year (at least))

Urban Areas (Town / cities)

Non-urban / Rural Areas

House No.

House No. and Ward

Road / Street Name

Name of Gram Panchayat / Village, etc:

Area / Locality

Name of Sub-Unit of District (Taluk / Tehsil / Other):

Ward / Corporation /Division

.....

Name of City / Town

Name of PHC / Sub Centre

Name of District (in Capitals) Postal Pin Code

Telephone No(s): Off. Res.

Mobile No. Email ID

9. Duration of Stay (at the permanent place of residence (in years))

10. Other Address:

10.1 Local Address

.....
.....

Name of City/Town/District.....

Pin Code

10.3 Native Place Address

.....
.....

Name of City/Town/District.....

Pin Code

10.2 Second (Office / Caretaker / Family Doctor) Address

.....
.....

Name of City/Town/District.....

Pin Code

11. Place of Birth

.....
.....

Name of City / Town / District.....

Pin Code

12. Age (in years)

Date of Birth

13. Age Estimated By:

- (1) Patient (2) Person Accompanying Patient (3) Social Investigator (8) Others (specify)..... (9) Unknown

14. Sex (1) Male (2) Female (8) Others

B. BASIC DEMOGRAPHIC PARAMETERS

1. Marital Status

- (1) Unmarried (2) Married (3) Widowed (4) Divorced (5) Separated (8) Others (specify)..... (9) Unknown

2. Mother Tongue

- (01) Assamese (02) Bengali (03) Gujarati (04) Hindi (05) Kannada (06) Kashmiri (07) Malayalam
 (08) Marathi (09) Oriya (10) Punjabi (11) Sanskrit (12) Sindhi (13) Tamil (14) Telugu
 (15) Urdu (16) English (17) Konkani (18) Bhutia (19) Manipuri (20) Mizo (21) Nepali
 (22) Lepcha (23) Rajasthani (88) Others (specify)..... (99) Unknown

3. Religion

- (1) Hindu (2) Muslim (3) Christian (4) Sikh
 (5) Jain (6) Neo-Budhist (7) Parsi (8) Indigenous Faith / Others (specify) (9) Unknown

4. Cultural Group / Background (Refer procedure manual for codes)

5. Education

- (1) Illiterate (2) Literate (3) Primary (4) Middle (5) Secondary
 (6) Technical after matric (7) College & Above (8) Others (specify)..... (9) Unknown

C. DIAGNOSTIC DETAILS

1. Diagnostic Status at Registration at Source of Registration / Reporting Institution (RI)

- (0) Not Registered at RI (1) Microscopically Confirmed
 (2) Suspected (Microscopically/Radiologically) (3) Unequivocal clinical Diagnosis
 (4) Suspected clinically/ To rule out Malignancy (8) Others (specify).....
 (9) Unknown

2. Method of Diagnosis

- (1) Clinical Only (2) Microscopic (3) X-Ray / Imaging Techniques
 (8) Others (specify)..... (9) Unknown

Microscopic (if 2 above)

- (1) Histology of Primary
 (2) Histology of Metastasis
 (4) Bone Marrow
 (5) Blood film
 (6) Cytology of Primary
 (7) Cytology of Metastasis
 (10) Flowcytometry
 (11) Cytogenetics
 (12) IHC
 (8) Others (specify).....

X-Ray / Imaging Techniques (if 3 above)

- (1) X-Ray
 (2) Isotopes
 (3) Angiography
 (4) Ultrasonogram
 (5) CT
 (6) MRI
 (7) PET scan
 (8) All Others (Specify).....

Others (if 8 above)

- (1) Endoscopy
 (2) Surgery without Histology
 (3) Specific Biochemical and/or Immunological Tests
 Specify Test(s).....
 (8) Others (specify).....

3. Anatomical Site of Specimen / Biopsy / smear

4. Complete Pathological Diagnosis: (With complete of Primary Site of Tumour and Morphological Diagnosis)

4.1. Primary Site of Tumour – Topography

4.2. Morphology / Histology

4.3. Pathology Slide No.

Date

dd mm yyyy

5. Coding According to ICD- O- 3:

5.1 Primary Site of Tumor - Topography **C**

(Include sub-site if any)

5.2 Primary Histology - Morphology **M**

If morphology is that of metastasis mention Primary Site above and

3. Major dietary pattern 1) Vegetarian 2) Non-vegetarian 3) Mixed Diet

3.1 Predominant Cooking Medium:

1) Mustard 2) Groundnut 3) Sunflower 4) Palm 5) Coconut 6) Ghee 8) Others, specify.....

4. Past History of

a. Gallbladder disease

1) Yes 2) No 9) Unknown

If yes, specify.....

Duration: (1) Months (2) Years

Enter Months/ Years

b. Details of Gallbladder surgery

1) Yes 2) No

If yes, specify

Date of previous Gallbladder surgery

dd mm yyyy

5. Associated Gallbladder Related factors

(a) Cholelithiasis

1) Yes 2) No

If Yes, Duration: (1) Months (2) Years

Enter Months/ Years

(b) Cholecystitis

1) Yes 2) No

If Yes, Duration: (1) Months (2) Years

Enter Months/ Years

(c) Porcelain gallbladder

1) Yes 2) No

If Yes, Duration: (1) Months (2) Years

Enter Months/ Years

(d) Gallbladder polyps

1) Yes 2) No

If Yes, Duration: (1) Months (2) Years

Enter Months/ Years

(e) Congenital biliary cysts

1) Yes 2) No

If Yes, Duration: (1) Months (2) Years

Enter Months/ Years

(f) Pancreaticobiliary Maljunction Anomalies

1) Yes 2) No

If Yes, Duration: (1) Months (2) Years

Enter Months/ Years

(g) Cholangitis

1) Yes 2) No

If Yes, Duration: (1) Months (2) Years

Enter Months/ Years

(h) Others, specify.....

1) Yes 2) No

6. Infections

1) Yes 2) No

If yes:

(a) Salmonella

1) Yes 2) No 9) Unknown

If Yes, Duration: (1) Months (2) Years

Enter Months/ Years

(b) Helicobacter

1) Yes 2) No 9) Unknown

If Yes, Duration: (1) Months (2) Years

Enter Months/ Years

(c) Liver Fluke

1) Yes 2) No 9) Unknown

If Yes, Duration: (1) Months (2) Years

Enter Months/ Years

(d) Biliary Tracts

1) Yes 2) No 9) Unknown

If Yes, Duration: (1) Months (2) Years

Enter Months/ Years

(e) Others (Specify) 1) Yes 2) No

7. Exposure to drugs

(a) Isoniazid

1) Yes 2) No

If Yes, Duration: (1) Months (2) Years

Enter Months/ Years

(b) Methyldopa

1) Yes 2) No

If Yes, Duration: (1) Months (2) Years

Enter Months/ Years

(c) Oral Contraceptive Drugs

1) Yes 2) No

If Yes, Duration: (1) Months (2) Years

Enter Months/ Years

(d) Hormone replacement therapy (HRT)

1) Yes 2) No

Yes, Duration: (1) Months (2) Years

Enter Months/ Years

(e) Others, specify.....

1) Yes 2) No

8. Family history of any Cancer

1) Yes

2) No

If yes, specify (degree/type)

9. Family history of gall stones

1) Yes

2) No

If yes, specify

10. Significant Past and Present Co-Morbid Conditions

(a) Tuberculosis

1) Yes 2) No

If Yes, Date of Onset:

Date of Treatment Completion:

(b) COPD

1) Yes 2) No

If Yes, Date of Onset:

(c) Hypertension

1) Yes 2) No

If Yes, Date of Onset:

(d) Hepatitis B

1) Yes 2) No

If Yes, Date of Onset:

- (e) Diabetes 1) Yes 2) No If Yes, Date of Onset:
- (f) Hepatitis C 1) Yes 2) No If Yes, Date of Onset:
- (g) Ischaemic Heart Disease 1) Yes 2) No If Yes, Date of Onset:
- (h) AIDS/ HIV +ve 1) Yes 2) No If Yes, Date of Onset:
- (i) Bronchial Asthma 1) Yes 2) No If Yes, Date of Onset:
- (j) Allergic Conditions (specify)..... 1) Yes 2) No If Yes, Duration: (1) Months (2) Years Enter Months/ Years
- (k) Others (specify)..... 1) Yes 2) No

F. OTHER DIAGNOSTIC DETAILS

1. Presenting features (1) Upfront (2) Post Surgery Duration (in months)
- a) Abdominal pain 1) Yes 2) No
- b) Anorexia 1) Yes 2) No
- c) Weight loss 1) Yes 2) No
- d) Vomiting 1) Yes 2) No
- e) Fever 1) Yes 2) No
- f) Jaundice 1) Yes 2) No
- g) Ascites 1) Yes 2) No
- h) Symptoms of Gastric Outlet Obstruction 1) Yes 2) No
- i) Liver Palpable Mass 1) Yes 2) No
- j) Gallbladder Palpable Mass 1) Yes 2) No
- k) Supraclavicular Lymph Nodes 1) Yes 2) No
- l) Imaging Presentation 1) Yes 2) No If yes, Specify
- m) Others, specify..... 1) Yes 2) No

2. Anthropometric measurements

- 2.1. Height (in cms) 2.2. Weight (in kgs) 2.3. BMI (Body Mass Index)

3. Blood parameters (as done at RI / prior to starting treatment)

- a) Blood group: 1) Yes 2) No If Yes, 1) A 2) B 3) AB 4) O
- Rhesus factor (Rh) 1) Positive (+) 2) Negative (-)
- b) Hemoglobin (Hb) level (g/dL)
- c) FBS (mg/dL)
- d) HBsAg 1) Yes 2) No If Yes, 1) Positive (+) 2) Negative (-)
- e) HCV 1) Yes 2) No If Yes, 1) Positive (+) 2) Negative (-)
- f) Cholesterol (mg/dL)
- g) INR 1) Yes 2) No If Yes,
- h) Albumin (g/dL)
- i) Alkaline phosphatase (IU/L)
- j) SGOT (AST)
- k) SGPT (ALT)

l) Serum LDH level (Units/L)

m) GGT (Gamma-glutamyl transpeptidase) (Units/L)

n) Bilirubin

i. Total (mg/dL)

ii. Direct (mg/dL)

iii. Indirect (mg/dL)

o) AFP 1) Yes 2) No If Yes, (ng/mL)

p) CEA (Carcinoembryonic antigen) (ng/mL) 1) Yes 2) No If Yes, (ng/mL)

q) CA19.9 (U/mL) 1) Yes 2) No If Yes, (U/mL)

4. Details of imaging findings:

4.1 Imaging Characteristic

4.1.1 Mucosal irregularity

If present, mention diagnostic protocol:

1) Present 2) Absent 3) Not Done 4) PET CT

1) USG

2) CT

3) MRI

4) PET CT

4.1.2 Discontinuous Mucosa

If present, mention diagnostic protocol:

1) Present 2) Absent 3) Not Done 4) PET CT

1) USG

2) CT

3) MRI

4) PET CT

4.1.3 Echogenic Mucosa

If present, mention diagnostic protocol:

1) Present 2) Absent 3) Not Done 4) PET CT

1) USG

2) CT

3) MRI

4) PET CT

4.1.4 Submucosal Echolucency

If present, mention diagnostic protocol:

1) Present 2) Absent 3) Not Done 4) PET CT

1) USG

2) CT

3) MRI

4) PET CT

4.1.5 Wall Thickening

If present, mention diagnostic protocol:

1) Present 2) Absent 3) Not Done 4) PET CT

1) USG

2) CT

3) MRI

4) PET CT

Mention Wall Thickness (mm)

4.1.6 Calcification of the wall

If present, mention diagnostic protocol:

1) Present 2) Absent 3) Not Done 4) PET CT

1) USG

2) CT

3) MRI

4) PET CT

Mention Type

1) Focal

2) Diffused

4.1.7 Cholelithiasis

If present, mention diagnostic protocol:

1) Present 2) Absent 3) Not Done 4) PET CT

1) USG

2) CT

3) MRI

4) PET CT

a. Number of gall stones

1) Single

2) Multiple

b. Size of the largest stone (in mm)

4.1.8 Intrahepatic biliary radical dilatation

If present, mention diagnostic protocol:

1) Present 2) Absent 3) Not Done 4) PET CT

1) USG

2) CT

3) MRI

4) PET CT

4.1.9 Extrahepatic biliary tract dilatation

If present, mention diagnostic protocol:

1) Present 2) Absent 3) Not Done 4) PET CT

1) USG

2) CT

3) MRI

4) PET CT

4.2.0 Gallbladder Polyps

If present, mention diagnostic protocol:

1) Present 2) Absent 3) Not Done 4) PET CT

1) USG

2) CT

3) MRI

4) PET CT

Number of Gallbladder Polyps

1) Single

2) Multiple

4.2.1 Choledochal Cyst

If present, mention diagnostic protocol:

1) Present 2) Absent 3) Not Done 4) PET CT

1) USG

2) CT

3) MRI

4) PET CT

4.2.2 Cholangitis

If present, mention diagnostic protocol:

1) Present 2) Absent 3) Not Done 4) PET CT

1) USG

2) CT

3) MRI

4) PET CT

4.2.3 Adenomyomatosis

If present, mention diagnostic protocol:

1) Present 2) Absent 3) Not Done 4) PET CT

1) USG

2) CT

3) MRI

4) PET CT

4.2.4 Gallbladder Mass

If present, mention diagnostic protocol:

1) Present 2) Absent 3) Not Done 4) PET CT

1) USG

2) CT

3) MRI

4) PET CT

a. If present, Location

1) Fundus

2) Body

3) Neck

4) Cystic duct

b. Size (in mm)

4.2.5 Anomalous Pancreatobiliary duct junction

If present, mention diagnostic protocol:

1) Present 2) Absent 3) Not Done 4) PET CT

1) USG

2) CT

3) MRI

4) PET CT

4.2.6 Cholesterosis

If present, mention diagnostic protocol:

1) Present 2) Absent 3) Not Done 4) PET CT

1) USG

2) CT

3) MRI

4) PET CT

4.2.7 Nodal Involvement

If present, mention diagnostic protocol:

a. Size of largest node (mm)

b. Involved nodal stations:

1. Pericholedochal

2. Periportal

3. Peripancreatic

4. Retroduodenal

5. Celiac

6. Interaortocaval

7. Superior mesenteric

8. Others (specify)

1) Present 2) Absent

3) Not Done

1) USG

2) CT

3) MRI

4) PET CT

4.2.8 Infiltration/ Involvement of adjacent organs:

1. Liver by Direct invasion

If present, mention diagnostic protocol:

1) Present

2) Absent

3) Not Done

1) USG

2) CT

3) MRI

4) PET CT

2. Liver by Metastases

If present, mention diagnostic protocol:

1) Present

2) Absent

3) Not Done

1) USG

2) CT

3) MRI

4) PET CT

3. Common Bile duct(s)

If present, mention diagnostic protocol:

1) Present

2) Absent

3) Not Done

1) USG

2) CT

3) MRI

4) PET CT

4. Confluence Involvement

If present, mention diagnostic protocol:

1) Present

2) Absent

3) Not Done

1) USG

2) CT

3) MRI

4) PET CT

5. Hepatic artery

If present, mention diagnostic protocol:

1) Present

2) Absent

3) Not Done

1) USG

2) CT

3) MRI

4) PET CT

6. Portal vein

If present, mention diagnostic protocol:

1) Present

2) Absent

3) Not Done

1) USG

2) CT

3) MRI

4) PET CT

7. Other adjacent organ

If present, mention diagnostic protocol:

1) Present

2) Absent

3) Not Done

1) USG

2) CT

3) MRI

4) PET CT

Specify.....

5. Metastatic workup

If done, specify imaging done

1) Done

2) Not done

1) USG

2) CT Thorax

3) Bone Scan

4) PETCT

5) others Specify.....

6. Pathology details for Resected Specimen:

Surgical Resection

If done,

1) Done

2) Not done

6.1 Date of receiving specimen

dd mm yyyy

6.2 Location of tumor:

1) Fundus

2) Body

3) Neck

4) Cystic duct

6.3 pT size:

(mm) x (mm) x (mm)

6.4 Gross appearance:

1) Papillary

2) Tubular

3) Nodular

6.5 Growth pattern:

1) Exophytic

2) Endophytic

6.6 Infiltration of adjacent structures:

1) None

2) Liver

3) Stomach

4) Colon

5) Duodenum

6) Coeliac Lymph Nodes

7) CBD

8) Others, specify.....

6.7 Cystic duct margin:

1) Involved

2) Dysplasia/CIS

3) Uninvolved

4) Not reported

If uninvolved, state the closest margin in mm

6.8 Liver parenchymal margin:

1) Involved

2) Uninvolved

3) Not reported

6.9 Other margins

1) Involved

2) Uninvolved

3) Not reported

If involved, state the site of involved margin

If uninvolved, state the closest margin in cm

6.10 Lymphovascular Invasion:

1) Present

2) Absent

3) Not reported

6.11 Perineural Invasion:

1) Present

2) Absent

3) Not reported

6.12 LN dissected:

1) Done

2) Not done

If Done,

6.12.1.1 Number of LN positive

6.12.1.2 Size of largest node (in mm x mm)

X

6.13 Interaortocaval node:

1) Positive

2) Negative

3) Not dissected

6.14 Additional findings:

6.14.1 Fibrosis

1) Present

2) Absent

3) Not Done

6.14.2 Surrounding Dysplasia

1) Present

2) Absent

3) Not Done

6.14.3 Adenoma	1) Present	2) Absent	3) Not Done	<input type="checkbox"/>	
6.14.4 Cholecystitis	1) Present	2) Absent	3) Not Done	<input type="checkbox"/>	
If Present:	1) Acute	2) Chronic		<input type="checkbox"/>	
6.14.5 Adenomyomatosis	1) Present	2) Absent	3) Not Done	<input type="checkbox"/>	
6.14.6 Xanthogranulomatosis	1) Present	2) Absent	3) Not Done	<input type="checkbox"/>	
6.14.7 Rokitansky Aschoff Sinuses	1) Present	2) Absent	3) Not Done	<input type="checkbox"/>	
6.15 pT stage:	1) Tx	2) T0	3) T1a	4) T1b	<input type="checkbox"/>
	5) T2a	6) T2b	7) T3	8) T4	<input type="checkbox"/>
6.16 pN stage:	1) NX	2) N0	3) N1	4) N2	<input type="checkbox"/>
6.17 Immunohistochemistry:					
a. P53	1) Positive	2) Negative	3) Not done	<input type="checkbox"/>	
b. P16	1) Positive	2) Negative	3) Not done	<input type="checkbox"/>	
c. EGFR	1) Positive	2) Negative	3) Not done	<input type="checkbox"/>	
d. ErbB2 (Her2)	1) Positive	2) Negative	3) Not done	<input type="checkbox"/>	
6.18 Molecular/Genetic investigations:					
a. KRAS	1) Mutated	2) Not mutated	3) Not done	<input type="checkbox"/>	
b. MSI	1) High	2) Low	3) Not done	<input type="checkbox"/>	
c. LOH	1) Present	2) Absent	3) Not done	<input type="checkbox"/>	
7. Other Investigations	1) Yes	2) No	<input type="checkbox"/>	If Yes, Specify	

G. FINAL DETAILS OF STAGING

1. TNM:

1.1 T stage:	1) Tx	2) T0	3) T1	4) T2	5) T3	6) T4	<input type="checkbox"/>
Sub stage:	1) a	2) b					<input type="checkbox"/>
1.2 N stage:	1) Nx	2) N0	3) N1	4) N2			<input type="checkbox"/>
1.3 M stage:	1) Mx	2) M0	3) M1				<input type="checkbox"/>
1.4 Stage grouping:	1) I	2) II	3) III	4) IV			<input type="checkbox"/>
Subgroup:	1) A	2) B					<input type="checkbox"/>

H. DETAILS OF CANCER DIRECTED TREATMENT (CDT)

1. Treatment at Reporting Institution

1.1 Intention to Treat	(1) Curative/Radical	(2) Salvage	(3) Palliative	(4) Supportive Care	<input type="checkbox"/>
If palliative yes,					<input type="checkbox"/>
(1) Palliative RT	<input type="checkbox"/>	(2) Palliative Chemotherapy	<input type="checkbox"/>		<input type="checkbox"/>
(3) Palliative Surgery	<input type="checkbox"/>	(4) Palliative Biliary Drainage Procedure (Specify).....	<input type="checkbox"/>		<input type="checkbox"/>
(5) Pain & Symptom Relief Drugs (specify)	<input type="checkbox"/>	(8) Others (specify)	<input type="checkbox"/>		<input type="checkbox"/>

1.2 Type of Cancer Directed Treatment Planned at Reporting Institution

	Yes	No
(1) Surgery	<input type="checkbox"/>	<input type="checkbox"/>
(2) Chemotherapy	<input type="checkbox"/>	<input type="checkbox"/>
(3) Radiotherapy	<input type="checkbox"/>	<input type="checkbox"/>
(4) Drainage Procedures (specify)	<input type="checkbox"/>	<input type="checkbox"/>
(8) Others (specify).....	<input type="checkbox"/>	<input type="checkbox"/>

2. ECOG Performance Status Score at Presentation (0 to 5):

- (0) Fully active, able to carry on all pre-disease performance without restriction.
- (1) Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.
- (2) Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.
- (3) Capable of only limited self care, confined to bed or chair more than 50% of waking hours.
- (4) Completely disabled. Cannot carry on any self care. Totally confined to bed or chair
- (5) Dead

3. Surgery

1) Yes	2) No	<input type="checkbox"/>
If Yes,		

3.1 Date of admission
dd mm yyyy

Date of surgery
dd mm yyyy

3.2 Staging Laparoscopy Done 1) Yes 2) No

3.3.1 If yes, state the Intraoperative findings:

- | | | | | |
|--|--------|-----------------|-----------------|--------------------------|
| a. GB fossa mass | 1) Yes | 2) No | 9) Unknown | <input type="checkbox"/> |
| b. Contiguous liver involvement | 1) Yes | 2) No | 9) Unknown | <input type="checkbox"/> |
| c. Regional LN enlarged | 1) Yes | 2) No | 9) Unknown | <input type="checkbox"/> |
| d. Extension to adjacent organs | 1) Yes | 2) No | 9) Unknown | <input type="checkbox"/> |
| If yes, 1) Colon 2) Stomach | | 3) Biliary tree | 4) Duodenum/HOP | <input type="checkbox"/> |
| e. Hepatic artery/portal vein invasion | 1) Yes | 2) No | 9) Unknown | <input type="checkbox"/> |
| f. Liver metastases | 1) Yes | 2) No | 9) Unknown | <input type="checkbox"/> |
| g. Omental/Peritoneal nodules | 1) Yes | 2) No | 9) Unknown | <input type="checkbox"/> |
| h. Ascites | 1) Yes | 2) No | 9) Unknown | <input type="checkbox"/> |
| i. Non Regional Nodes | 1) Yes | 2) No | 9) Unknown | <input type="checkbox"/> |
| j. Others, specify | 1) Yes | 2) No | 9) Unknown | <input type="checkbox"/> |

3.4 Route of surgery 1) Open 2) Laproscopic 3) Robotic 4) Laparoscopy converted to Open

3.5 Extent of surgery 1) Biopsy alone 2) Simple cholecystectomy
 3) Extended Cholecystectomy with CBD 4) Extended Cholecystectomy with CBD & Viscera
 5) Extended Cholecystectomy with lymphadenectomy 6) Partial Cholecystotomy

3.6 Liver resection done 1) Yes 2) No
 If yes, Extent of liver resection: 1) Wedge resection 2) Rt Hepatectomy
 3) Segmental (Specify segments 1-9)..... 4) Extended Rt hepatectomy

3.7 Resection of other adjacent organs 1) Yes 2) No
 If yes, a) Pancreas b) Duodenum
 c) Stomach d) Omentum
 e) Colon f) Common Bile Duct (Extrahepatic biliary tract)
 g) Vessel- Portal Vein/Hepatic artery h) Others, Specify

3.8 Lymphadenectomy 1) Yes 2) No
 If yes, specify the nodal levels dissected: 1) Hepatoduodenal ligament nodes 2) Retroduodenal nodes 3) Periportal nodes
 4) Interaortocaval nodes 5) Pericholedochal nodes 6) Celiac nodes
 7) Peripancreatic nodes 10) Superior mesenteric nodes 8) Others, Specify

3.9 Reconstruction done 1) Yes 2) No If yes, specify

3.10 Port site excision (If Lap/ Robotic) 1) Done 2) Not done

3.11 Intraoperative bile spillage 1) Yes 2) No

3.12 Stent placement done: 1) Yes 2) No

If yes, specify 1) Endoscopic 2) Percutaneous

3.13 Portal vein embolization 1) Done 2) Not done

3.14 Any additional Operative Details (including need for additional surgery)

3.15 Complications and post-operative morbidity- prolonging ward stay/repeat exploration:

- | | | | |
|---|--------|-------|--------------------------|
| a. Intra-abdominal bleeding | 1) Yes | 2) No | <input type="checkbox"/> |
| b. Biliary fistula/leak/stricture | 1) Yes | 2) No | <input type="checkbox"/> |
| c. Cholangitis | 1) Yes | 2) No | <input type="checkbox"/> |
| d. Bowel Injury | 1) Yes | 2) No | <input type="checkbox"/> |
| e. Wound infection | 1) Yes | 2) No | <input type="checkbox"/> |
| f. Need for PPV (Positive Pressure Ventilation) | 1) Yes | 2) No | <input type="checkbox"/> |
| g. Need for BT (Blood Transfusion) | 1) Yes | 2) No | <input type="checkbox"/> |
| h. Other, Specify | 1) Yes | 2) No | <input type="checkbox"/> |
| i. Death | 1) Yes | 2) No | <input type="checkbox"/> |

3.16 Date of discharge

dd		mm		yyyy			

4. Chemotherapy

1) Yes 2) No

If Yes,

4.1 BSA (Body Surface Area)

--	--	--	--	--	--

4.2 Chemotherapy: 1) Adjuvant 2) Neoadjuvant 3) Concurrent 4) Palliative

4.3 First Line Chemotherapy: 1) Yes 2) No

If Yes,

4.3.1 Date of start

dd		mm		yyyy			

4.3.2 Regimen followed:

Drug	Dose	Dosing frequency								
Gemcitabine (mg/m ²)	<table border="1"><tr><td> </td><td> </td><td> </td></tr></table>				Days <table border="1"><tr><td> </td><td> </td></tr></table>			Cycles <table border="1"><tr><td> </td><td> </td></tr></table>		
Cisplatin (mg/m ²)	<table border="1"><tr><td> </td><td> </td><td> </td></tr></table>				Days <table border="1"><tr><td> </td><td> </td></tr></table>			Cycles <table border="1"><tr><td> </td><td> </td></tr></table>		
Oxaliplatin (mg/m ²)	<table border="1"><tr><td> </td><td> </td><td> </td></tr></table>				Days <table border="1"><tr><td> </td><td> </td></tr></table>			Cycles <table border="1"><tr><td> </td><td> </td></tr></table>		
Capecitabine (mg/m ²)	<table border="1"><tr><td> </td><td> </td><td> </td></tr></table>				Days <table border="1"><tr><td> </td><td> </td></tr></table>			Cycles <table border="1"><tr><td> </td><td> </td></tr></table>		
5 FU (mg/m ²)	<table border="1"><tr><td> </td><td> </td><td> </td></tr></table>				Days <table border="1"><tr><td> </td><td> </td></tr></table>			Cycles <table border="1"><tr><td> </td><td> </td></tr></table>		
Irinotecan (mg/m ²)	<table border="1"><tr><td> </td><td> </td><td> </td></tr></table>				Days <table border="1"><tr><td> </td><td> </td></tr></table>			Cycles <table border="1"><tr><td> </td><td> </td></tr></table>		
Carboplatin (AUC- mg)	<table border="1"><tr><td> </td><td> </td><td> </td></tr></table>				Days <table border="1"><tr><td> </td><td> </td></tr></table>			Cycles <table border="1"><tr><td> </td><td> </td></tr></table>		
Others	<table border="1"><tr><td> </td><td> </td><td> </td></tr></table>				Days <table border="1"><tr><td> </td><td> </td></tr></table>			Cycles <table border="1"><tr><td> </td><td> </td></tr></table>		

4.3.3 Number of cycles planned

4.3.4 Number of cycles completed

4.3.5 Toxicity (If Grade 3 & above)

- | | | | |
|---|---|---|--------------------------|
| <input type="checkbox"/> a) Myelosuppression | <input type="checkbox"/> b) Nausea/Vomiting | <input type="checkbox"/> c) Neurotoxicity | <input type="checkbox"/> |
| <input type="checkbox"/> d) Ototoxicity | <input type="checkbox"/> e) Nephrotoxicity | <input type="checkbox"/> f) Elevation of LFTs | <input type="checkbox"/> |
| <input type="checkbox"/> g) Electrolyte abnormalities | <input type="checkbox"/> h) Diarrhea | <input type="checkbox"/> i) Fatigue | <input type="checkbox"/> |
| <input type="checkbox"/> j) Skin Rash | <input type="checkbox"/> k) Oral Mucositis | <input type="checkbox"/> l) Others | <input type="checkbox"/> |

4.3.6 Response:

- | | | | |
|---|--|--|--------------------------|
| <input type="checkbox"/> 1) Complete response | <input type="checkbox"/> 2) Partial response | <input type="checkbox"/> 3) Stable disease | <input type="checkbox"/> |
| <input type="checkbox"/> 4) Progressive disease | <input type="checkbox"/> 5) Not assessable/ not applicable | <input type="checkbox"/> 6) Defaulted (specify cause)..... | <input type="checkbox"/> |

4.3.7 Date of completion

dd		mm		yyyy			

4.3.8 CT Completed as planned 1) Yes 2) No

If no, specify cause

4.4 Second Line Chemotherapy 1) Yes 2) No

If Yes,

4.4.1 Date of start

dd		mm		yyyy			

4.4.2 Regimen followed:

Drug	Dose	Dosing frequency								
Gemcitabine (mg/m ²)	<table border="1"><tr><td> </td><td> </td><td> </td></tr></table>				Days <table border="1"><tr><td> </td><td> </td></tr></table>			Cycles <table border="1"><tr><td> </td><td> </td></tr></table>		
Cisplatin (mg/m ²)	<table border="1"><tr><td> </td><td> </td><td> </td></tr></table>				Days <table border="1"><tr><td> </td><td> </td></tr></table>			Cycles <table border="1"><tr><td> </td><td> </td></tr></table>		
Oxaliplatin (mg/m ²)	<table border="1"><tr><td> </td><td> </td><td> </td></tr></table>				Days <table border="1"><tr><td> </td><td> </td></tr></table>			Cycles <table border="1"><tr><td> </td><td> </td></tr></table>		
Capecitabine (mg/m ²)	<table border="1"><tr><td> </td><td> </td><td> </td></tr></table>				Days <table border="1"><tr><td> </td><td> </td></tr></table>			Cycles <table border="1"><tr><td> </td><td> </td></tr></table>		
5 FU (mg/m ²)	<table border="1"><tr><td> </td><td> </td><td> </td></tr></table>				Days <table border="1"><tr><td> </td><td> </td></tr></table>			Cycles <table border="1"><tr><td> </td><td> </td></tr></table>		
Irinotecan (mg/m ²)	<table border="1"><tr><td> </td><td> </td><td> </td></tr></table>				Days <table border="1"><tr><td> </td><td> </td></tr></table>			Cycles <table border="1"><tr><td> </td><td> </td></tr></table>		
Carboplatin (AUC- mg)	<table border="1"><tr><td> </td><td> </td><td> </td></tr></table>				Days <table border="1"><tr><td> </td><td> </td></tr></table>			Cycles <table border="1"><tr><td> </td><td> </td></tr></table>		
Others	<table border="1"><tr><td> </td><td> </td><td> </td></tr></table>				Days <table border="1"><tr><td> </td><td> </td></tr></table>			Cycles <table border="1"><tr><td> </td><td> </td></tr></table>		

4.4.3 Number of cycles planned

4.4.4 Number of cycles completed

4.4.5 Toxicity (If Grade 3 & Above)

- | | | | |
|---|---|---|--------------------------|
| <input type="checkbox"/> a) Myelosuppression | <input type="checkbox"/> b) Nausea/Vomiting | <input type="checkbox"/> c) Neurotoxicity | <input type="checkbox"/> |
| <input type="checkbox"/> d) Ototoxicity | <input type="checkbox"/> e) Nephrotoxicity | <input type="checkbox"/> f) Elevation of LFTs | <input type="checkbox"/> |
| <input type="checkbox"/> g) Electrolyte abnormalities | <input type="checkbox"/> h) Diarrhea | <input type="checkbox"/> i) Fatigue | <input type="checkbox"/> |
| <input type="checkbox"/> j) Skin Rash | <input type="checkbox"/> k) Oral Mucositis | <input type="checkbox"/> l) Others | <input type="checkbox"/> |

4.4.6 Response:

- | | | | |
|---|--|---|--------------------------|
| <input type="checkbox"/> 1) Complete response | <input type="checkbox"/> 2) Partial response | <input type="checkbox"/> 3) Stable disease | <input type="checkbox"/> |
| <input type="checkbox"/> 4) Progressive disease | <input type="checkbox"/> 5) Not assessable/ Not applicable | <input type="checkbox"/> 6) Defaulted (specify cause) | |

4.4.7 Date of completion

<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
dd		mm		yyyy			

4.4.8 CT Completed as planned

- | | | |
|---------------------------------|--------------------------------|--------------------------|
| <input type="checkbox"/> 1) Yes | <input type="checkbox"/> 2) No | <input type="checkbox"/> |
|---------------------------------|--------------------------------|--------------------------|
- If no, specify cause.....

5. Targeted therapy given:

- | | | |
|---------------------------------|--------------------------------|--------------------------|
| <input type="checkbox"/> 1) Yes | <input type="checkbox"/> 2) No | <input type="checkbox"/> |
|---------------------------------|--------------------------------|--------------------------|
- If yes,

5.1.1 Date of start

<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
dd		mm		yyyy			

5.1.2 Drug administered

Target	Name of the drug	Dose	Dosing frequency	
EGFR		<input type="text"/>	Days <input type="text"/>	Cycles <input type="text"/>
VEGF		<input type="text"/>	Days <input type="text"/>	Cycles <input type="text"/>
Her2		<input type="text"/>	Days <input type="text"/>	Cycles <input type="text"/>
Immunotherapy		<input type="text"/>	Days <input type="text"/>	Cycles <input type="text"/>
Others		<input type="text"/>	Days <input type="text"/>	Cycles <input type="text"/>

5.1.3 Number of cycles planned

<input type="text"/>	<input type="text"/>
----------------------	----------------------

5.1.4 Number of cycles completed

<input type="text"/>	<input type="text"/>
----------------------	----------------------

5.1.5 Toxicity (If Grade 3 & above)

- | | | | |
|---|---|---|--------------------------|
| <input type="checkbox"/> a) Myelosuppression | <input type="checkbox"/> b) Nausea/Vomiting | <input type="checkbox"/> c) Neurotoxicity | <input type="checkbox"/> |
| <input type="checkbox"/> d) Ototoxicity | <input type="checkbox"/> e) Nephrotoxicity | <input type="checkbox"/> f) Elevation of LFTs | <input type="checkbox"/> |
| <input type="checkbox"/> g) Electrolyte abnormalities | <input type="checkbox"/> h) Diarrhea | <input type="checkbox"/> i) Fatigue | <input type="checkbox"/> |
| <input type="checkbox"/> j) Skin Rash | <input type="checkbox"/> k) Oral Mucositis | <input type="checkbox"/> l) Others | <input type="checkbox"/> |

5.1.6 Response

- | | | | |
|---|--|--|--------------------------|
| <input type="checkbox"/> 1) Complete response: | <input type="checkbox"/> 2) Partial response | <input type="checkbox"/> 3) Stable disease | <input type="checkbox"/> |
| <input type="checkbox"/> 4) Progressive disease | <input type="checkbox"/> 5) Not assessable/ Not applicable | <input type="checkbox"/> 6) Defaulted (specify cause.....) | |

5.1.7 Date of completion

<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
dd		mm		yyyy			

5.1.8 Targeted therapy completed as planned

- | | | |
|---------------------------------|--------------------------------|--------------------------|
| <input type="checkbox"/> 1) Yes | <input type="checkbox"/> 2) No | <input type="checkbox"/> |
|---------------------------------|--------------------------------|--------------------------|
- If no, specify cause.....

6. Radiotherapy

- | | | |
|--|---|--------------------------|
| <input type="checkbox"/> 6.1 (0) Radiotherapy (RT) not planned | <input type="checkbox"/> (1) Yes, RT given as planned | <input type="checkbox"/> |
| <input type="checkbox"/> (2) Yes, RT given, but incomplete (<i>Specify reason</i>) | <input type="checkbox"/> (3) RT planned but not taken (<i>Specify reason</i>) | |
| <input type="checkbox"/> (8) Others (<i>specify</i>) | | |

If 1 or 2 above,

- | | | | | |
|---|---------------------------------------|--|---|--------------------------|
| <input type="checkbox"/> 6.2 Intention to treat | <input type="checkbox"/> (1) Adjuvant | <input type="checkbox"/> (2) Neoadjuvant | <input type="checkbox"/> (3) Palliative | <input type="checkbox"/> |
|---|---------------------------------------|--|---|--------------------------|

6.3 Dose (in cGy)

<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
----------------------	----------------------	----------------------	----------------------

6.3.1 Number of fractions

<input type="text"/>	<input type="text"/>
----------------------	----------------------

6.3.2 Duration of treatment: Duration:

- | | | | |
|------------------------------------|-------------------------------------|--------------------------|--|
| <input type="checkbox"/> (1) Weeks | <input type="checkbox"/> (2) Months | <input type="checkbox"/> | Enter Weeks/ Months <input type="text"/> |
|------------------------------------|-------------------------------------|--------------------------|--|

6.4 Date of start

□ □ □ □ □ □ □ □

dd mm yyyy

Date of completion

□ □ □ □ □ □ □ □

dd mm yyyy

6.5 Technique: 1) Conventional 2) 3DCRT 3) IMRT 4) IMRT with IGRT (CT based)

6.6 Image guidance: 1) Yes 2) No

If yes, type of image guidance used: 1) Port film 2) EPID 3) CBCT 4) MVCT

Frequency of image guidance: 1) Daily 2) Weekly 3) At initiation of RT

6.7 Concurrent CT planned 1) Yes 2) No

If yes, Specify drug..... Dose Dosing frequency

6.8 Response:

1) Complete response: 2) Partial response 3) Stable disease

4) Progressive disease 5) Not assessable/ Not applicable 6) Defaulted (specify cause.....)

6.9 Adverse effects (If Grade 3 & above):

1) Skin 2) Upper GI toxicity 3) Lower GI toxicity 4) Myelosuppression

7. Palliative procedure 1) Yes 2) No

If Yes,

7.1 Surgical: 1) Yes 2) No

If yes, specify 1) Gastrojejunostomy 2) Triple bypass 3) Seg III Bypass

7.2 Non surgical: 1) Yes 2) No

If yes, specify:

1) Stent placement done 1) Yes 2) No

If yes, Specify type: 1) Duodenal 2) Biliary

Specify route: 1) Endoscopic 2) Percutaneous

2) Nerve Blocks If Yes, Specify

3) Ascitic Tap

4) Hemostatic RT

5) Others, Specify

8. Completion of Cancer Directed Treatment 1) Yes 2) No

8.1 If yes, Date of treatment completion

□ □ □ □ □ □ □ □

dd mm yyyy

8.2 If no, specify cause

1) Progressive Diseases 2) No response to treatment 3) Poor tolerance

4) Defaulted (lost to follow up) 5) Death

9. ECOG SCORE (0-5) at Treatment Completion

(0) Fully active, able to carry on all pre-disease performance without restriction

(1) Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work

(2) Ambulatory and capable of all self care but unable to carry out any work activities.

Up and about more than 50% of waking hours

(3) Capable of only limited self care, confined to bed or chair more than 50% of waking hours

(4) Completely disabled. Cannot carry on any self care. Totally confined to bed or chair

(5) Dead

10. Response assessment done 1) Yes 2) No

If Yes, Date of response assessment

□ □ □ □ □ □ □ □

dd mm yyyy

10.1 Response to CDT:

1) Complete response 2) Partial response 3) Stable disease 4) Progressive disease

11. Status at Treatment completion

(1) Alive (2) Dead

If Dead,

11.1 Cause of Death as per Medical Certificate of Cause of Death (MCCD)

(a) Immediate Cause ICD -10

(b) Antecedent Cause ICD -10

(c) Other Significant conditions.....

11.2 Date of Death

<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
<i>dd</i>		<i>mm</i>		<i>yyyy</i>			

12. Remarks (add additional sheet (s) if necessary)

FOLLOW-UP INFORMATION (USE SEPARATE PAGE FOR EACH VISIT) FOR GALLBLADDER CANCER

1. Due Date for follow up

<i>dd</i>		<i>mm</i>		<i>yyyy</i>			

Date of Actual Follow-up

<i>dd</i>		<i>mm</i>		<i>yyyy</i>			

Follow-up Visit No.

--	--

1.1 Method of Follow-up

- | | | |
|-----------------------|--------------------|--|
| (0) No follow-up | (1) Hospital visit | (2) By post |
| (3) Through telephone | (4) Home visit | (8) Others (<i>specify</i>) <input type="checkbox"/> |

1.2 Status at Follow-up

- | | |
|-----------|-----------------------------------|
| (1) Alive | (2) Dead <input type="checkbox"/> |
|-----------|-----------------------------------|

1.3 Disease Status (at Follow-up)

- | | | |
|--------------------------------------|---|-------------------------|
| (1) No Evidence of Disease | (2) Residual disease only | (3) Local recurrence |
| (4) Regional/Nodal recurrence | (5) Distant metastasis: <i>specify site</i> | (6) Progressive Disease |
| (9) Unknown <input type="checkbox"/> | | |

1.4 If (2) to (6) above: Date of Diagnosis/ Evaluation of Disease Status

<i>dd</i>		<i>mm</i>		<i>yyyy</i>			

1.5 If Disease is present, indicate Basis of Diagnosis

- | | | |
|--------------------|-------------------------------------|-----------------------------------|
| (1) Histopathology | (2) Cytopathology (Other than FNAC) | (3) FNAC <input type="checkbox"/> |
| (4) Bone Marrow | (5) Peripheral Smear | (6) Radiological |
| (7) Clinical | (8) Others (<i>specify</i>) | (9) Unknown |

1.6 Treatment: if 1.5 above indicates presence of disease

- | | |
|--------------------------|---------------------------------------|
| (1) Yes, Treatment given | (2) No Treatment, specify reason..... |
|--------------------------|---------------------------------------|

If Yes, Select treatment type

- | | | | |
|------------|-----------------|---------------|---|
| 1) Surgery | 2) Chemotherapy | 3) Palliative | 4) Supportive Care <input type="checkbox"/> |
|------------|-----------------|---------------|---|

1.7 If yes, Details of Treatment and Outcome (Use separate sheet if necessary)

1.8 Late Complications of CDT (1) Yes

(2) No

If Yes (Record if Grade III & above)

Date of Diagnosis

- (1) Bone Marrow Suppression
- (2) Nausea/ Vomiting
- (3) Renal Dysfunction
- (4) Neurotoxicity
- (5) GI Perforation
- (6) GI Obstruction

<i>dd</i>		<i>mm</i>		<i>yyyy</i>			

2. If Dead,

2.1 Cause of Death as per Medical Certificate of Cause of Death (MCCD)

- (a) Immediate Cause ICD -10
- (b) Antecedent Cause ICD -10
- (c) Other Significant conditions.....

2.2 Date of Death

<i>dd</i>		<i>mm</i>		<i>yyyy</i>			

3. Remarks (add additional sheet(s) if necessary)